JP2006505530A5 - - Google Patents

Download PDF

Info

Publication number
JP2006505530A5
JP2006505530A5 JP2004532517A JP2004532517A JP2006505530A5 JP 2006505530 A5 JP2006505530 A5 JP 2006505530A5 JP 2004532517 A JP2004532517 A JP 2004532517A JP 2004532517 A JP2004532517 A JP 2004532517A JP 2006505530 A5 JP2006505530 A5 JP 2006505530A5
Authority
JP
Japan
Prior art keywords
azabicyclo
oct
carboxamide
octane
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004532517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505530A (ja
Filing date
Publication date
Priority claimed from SE0202598A external-priority patent/SE0202598D0/xx
Application filed filed Critical
Publication of JP2006505530A publication Critical patent/JP2006505530A/ja
Publication of JP2006505530A5 publication Critical patent/JP2006505530A5/ja
Abandoned legal-status Critical Current

Links

JP2004532517A 2002-09-02 2003-09-01 アルファ−7ニコチン受容体作用剤およびスタチンの組み合わせ Abandoned JP2006505530A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202598A SE0202598D0 (sv) 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination
PCT/SE2003/001352 WO2004019947A1 (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and statins in combination

Publications (2)

Publication Number Publication Date
JP2006505530A JP2006505530A (ja) 2006-02-16
JP2006505530A5 true JP2006505530A5 (https=) 2006-10-19

Family

ID=20288874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004532517A Abandoned JP2006505530A (ja) 2002-09-02 2003-09-01 アルファ−7ニコチン受容体作用剤およびスタチンの組み合わせ

Country Status (12)

Country Link
US (2) US20050256146A1 (https=)
EP (1) EP1545537B9 (https=)
JP (1) JP2006505530A (https=)
AT (1) ATE358485T1 (https=)
AU (1) AU2003256203A1 (https=)
DE (1) DE60313004T2 (https=)
DK (1) DK1545537T3 (https=)
ES (1) ES2283860T3 (https=)
PT (1) PT1545537E (https=)
SE (1) SE0202598D0 (https=)
SI (1) SI1545537T1 (https=)
WO (1) WO2004019947A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
MX2010014203A (es) 2008-06-20 2011-02-22 Astrazeneca Ab Derivados de dibenzotiazepina y sus usos - 424.
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
WO2012007500A2 (de) * 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
AU2012231275A1 (en) * 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013161871A1 (ja) * 2012-04-25 2013-10-31 興和株式会社 Tlr阻害作用を有するチオフェン誘導体
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
HK1219722A1 (zh) 2013-06-21 2017-04-13 Takeda Pharmaceutical Company Limited 1-磺酰基派啶衍生物作为前动力蛋白受体的调节剂
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
US20210255202A1 (en) * 2018-06-13 2021-08-19 Michael R. D'Andrea Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903996D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
US20050222122A1 (en) * 2002-04-02 2005-10-06 Sean Lilienfeld Statin therapy for enhancing cognitive maintenance
KR20050085535A (ko) * 2002-12-11 2005-08-29 파마시아 앤드 업존 캄파니 엘엘씨 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
NZ550534A (en) * 2004-03-25 2009-07-31 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof

Similar Documents

Publication Publication Date Title
JP2006505530A5 (https=)
US20090192180A1 (en) Alpha-7 Nicotinic Receptor Agonists and Statins In Combination
RU2002118302A (ru) Новые биарилкарбоксамиды
JP2003514818A5 (https=)
JP2006528685A5 (https=)
JP2002523502A5 (https=)
RU2008148902A (ru) Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3)
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
JP2012523437A5 (https=)
HRP20171793T1 (hr) Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata
AU2007271186B2 (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
JP2008526861A5 (https=)
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
JP2009514802A5 (https=)
JP2014503568A (ja) ニコチン酸アセチルコリン受容体α7活性化因子の使用
RU2007134414A (ru) Бензоксазолкарбоксамиды для лечения индуцированной химиотерапией тошноты и рвоты (cini) и синдрома раздраженного кишечника с преобладанием диареи (ibs-d)
CN105263492B (zh) α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
RU2007126638A (ru) Профилактическое или терапевтическое средство для лечения расстройства сна
JP2005510482A5 (ja) 線維筋痛症候群の治療用医薬
US20050222193A1 (en) Novel combination for the treatment of airway disorders
AU2012232711B2 (en) Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
HK1077193B (en) Alpha-7 nicotinic receptor agonists and statins in combination
JP2005501066A (ja) パロキセチンおよび医薬上許容されるグリチルリチン酸塩を含む組成物
Paykel Antidepressants in the 1990s
AU2013203070B2 (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases